Allergic Rhinitis (Hay Fever)

Table of Contents

  1. What Is Allergic Rhinitis?
  2. Seasonal vs. Perennial Rhinitis
  3. The IgE-Mediated Allergic Cascade
  4. Symptoms and Diagnosis
  5. Allergen Testing
  6. Nasal Corticosteroids (First-Line Treatment)
  7. Antihistamines and Other Medications
  8. Allergen Immunotherapy (Allergy Shots and Drops)
  9. Environmental Control Strategies
  10. Research Papers
  11. Connections
  12. Featured Videos

What Is Allergic Rhinitis?

Allergic rhinitis (AR) is a chronic inflammatory condition of the nasal passages caused by IgE-mediated hypersensitivity reactions to inhaled allergens. It affects approximately 400 million people worldwide — roughly 10–30% of the adult population and up to 40% of children — making it one of the most prevalent chronic diseases globally. In the United States, AR affects an estimated 50 million Americans annually and costs the healthcare system over $11 billion per year in direct medical costs.

Despite its colloquial name "hay fever," the condition is not caused by hay, produces no fever, and occurs year-round in its perennial form. AR significantly impairs quality of life, disrupts sleep, reduces work and school productivity, and is strongly linked to the development of asthma, chronic sinusitis, nasal polyps, and otitis media.

Back to Table of Contents

Seasonal vs. Perennial Rhinitis

Allergic rhinitis is classified by its triggering allergens and time course:

Seasonal allergic rhinitis (SAR): Triggered by outdoor allergens with defined seasons:

Perennial allergic rhinitis (PAR): Triggered by indoor allergens present year-round:

Mixed rhinitis: Many patients have both SAR and PAR, with year-round baseline symptoms that spike during pollen seasons. The ARIA (Allergic Rhinitis and its Impact on Asthma) guidelines reclassify rhinitis as "intermittent" (symptoms <4 days/week or <4 consecutive weeks) or "persistent" (symptoms >4 days/week AND >4 consecutive weeks), regardless of cause.

Back to Table of Contents

The IgE-Mediated Allergic Cascade

Understanding the allergic mechanism helps patients understand why symptoms persist and how treatments work:

Sensitization (first exposure): Inhaled allergen particles (pollen, dander) are taken up by antigen-presenting cells in the nasal mucosa and presented to naive T helper (Th0) cells, which differentiate into Th2 cells. Th2 cells release IL-4 and IL-13, driving B cells to class-switch to IgE production. Allergen-specific IgE antibodies bind to high-affinity receptors (FcεRI) on mast cells and basophils throughout the nasal mucosa. The person is now sensitized — symptom-free but primed.

Early-phase reaction (minutes after re-exposure): When the same allergen enters a sensitized person's nose, it cross-links IgE molecules on mast cells, triggering immediate degranulation. Mast cells release pre-formed mediators — histamine, tryptase, leukotrienes — within seconds. Within 5–30 minutes: sneezing, itching, watery rhinorrhea, and nasal congestion appear. Histamine acts on H1 receptors on nerve endings (itch and sneeze) and blood vessels (vasodilation, increased permeability → congestion and rhinorrhea).

Late-phase reaction (4–8 hours later): Mast cell mediators recruit eosinophils, basophils, Th2 cells, and additional mast cells from the bloodstream. These cells amplify inflammation and produce sustained cytokine signals (IL-5, eotaxin) that maintain eosinophilic infiltration. This accounts for the ongoing nasal congestion and chronic mucosal changes seen in patients with persistent AR.

Priming effect: Repeated allergen exposure during pollen season progressively lowers the threshold for mast cell activation, so by mid-season, patients react to far lower pollen counts than at the start of the season. This explains why AR symptoms often worsen as the season progresses.

Comorbidities: The same Th2 immune skewing underlies asthma (the "unified airway disease" concept — nasal and bronchial mucosa share inflammatory pathways), eczema (atopic dermatitis), and food allergies. Up to 40% of AR patients have asthma; treating AR reduces asthma exacerbations.

Back to Table of Contents

Symptoms and Diagnosis

The classic symptom triad of AR is sneezing, rhinorrhea, and nasal congestion, accompanied by nasal/ocular/palatal itch.

Nasal symptoms:

Ocular symptoms (allergic conjunctivitis): Bilateral eye itching, redness, tearing, chemosis (conjunctival swelling). Present in 50–70% of AR patients; distinguishes AR from non-allergic rhinitis.

Oral/palate itch: Itching of the palate or pharynx; associated with pollen sensitization.

Systemic symptoms: Fatigue, irritability, difficulty concentrating, and poor sleep are common. AR impairs daytime cognitive function measurably — equivalent to a blood alcohol level of 0.05% in driving studies.

Physical exam findings: "Allergic shiners" (infraorbital darkening from venous congestion); pale, bluish-gray, boggy nasal turbinates (distinguishes AR from viral rhinitis which causes erythematous, swollen turbinates); cobblestoning of posterior pharynx.

Diagnosis: Based on clinical history and physical exam. Skin prick testing (SPT) or serum-specific IgE (ImmunoCAP/RAST) confirms allergen sensitization and guides immunotherapy.

Back to Table of Contents

Allergen Testing

Skin prick testing (SPT): A drop of standardized allergen extract is placed on the forearm or back; a lancet scratches through the drop into the skin. A positive test produces a wheal (raised bump) ≥3mm larger than the negative control within 15 minutes. SPT is rapid, inexpensive, highly sensitive, and the gold standard for identifying sensitization. It must be performed without antihistamines for 5–7 days beforehand.

Intradermal testing: A small amount of diluted allergen is injected into the skin; more sensitive than SPT but less specific (more false positives); used when SPT is negative but AR is strongly suspected clinically.

Serum-specific IgE (ImmunoCAP): A blood test measuring allergen-specific IgE antibodies; results reported in kUA/L (classes 0–6). Advantages: can be performed on patients who cannot stop antihistamines, those with severe skin conditions (eczema), or patients at risk for anaphylaxis. Correlates reasonably with SPT results; neither test perfectly predicts clinical severity.

Component-resolved diagnostics (CRD): Identifies sensitization to individual protein components within an allergen (e.g., Bet v 1 vs. Bet v 2 within birch pollen). CRD predicts risk of systemic reactions to immunotherapy and identifies patients with genuine pollen sensitization vs. those with food-pollen cross-reactivity.

Back to Table of Contents

Nasal Corticosteroids (First-Line Treatment)

Intranasal corticosteroids (INCs) are the most effective single treatment for AR and are recommended as first-line therapy by all major allergy guidelines (ARIA, AAAAI, ACAAI). They work by reducing the entire inflammatory cascade — mast cell recruitment, eosinophil accumulation, cytokine production, and vascular permeability — rather than just blocking one mediator.

Key points:

Back to Table of Contents

Antihistamines and Other Medications

Oral antihistamines: Second-generation antihistamines (cetirizine/Zyrtec, loratadine/Claritin, fexofenadine/Allegra, levocetirizine/Xyzal, desloratadine/Clarinex) are non-sedating at standard doses and appropriate for as-needed or daily use. They are most effective for sneezing, rhinorrhea, and itching but less effective for nasal congestion.

First-generation antihistamines (diphenhydramine/Benadryl, chlorpheniramine) cross the blood-brain barrier, causing significant sedation and cognitive impairment; they should generally be avoided in AR because they impair the very symptoms patients are trying to manage (driving, work, school).

Intranasal antihistamines: Azelastine (Astelin, Astepro) and olopatadine (Patanase) act directly on nasal mucosa with rapid onset (~15 minutes). Effective for intermittent AR and may provide faster relief than oral antihistamines; slight bitter taste is a common complaint. Combination INS+antihistamine (Dymista — fluticasone + azelastine) is the most effective pharmacological option for severe AR.

Decongestants: Pseudoephedrine (systemic) and oxymetazoline (Afrin — topical) reduce congestion through alpha-adrenergic vasoconstriction. Topical decongestants must be limited to 3–5 days to avoid rhinitis medicamentosa (rebound congestion); pseudoephedrine elevates blood pressure and heart rate, contraindicated in hypertension, prostate enlargement, anxiety, and insomnia.

Leukotriene receptor antagonists (LTRAs): Montelukast (Singulair) blocks cysteinyl leukotrienes; modestly effective for AR and asthma; second-line to INS. The FDA added a black box warning in 2020 for serious neuropsychiatric adverse events (suicidal ideation, aggression, depression).

Cromolyn sodium nasal spray: Stabilizes mast cells, preventing degranulation; most effective when started 2 weeks before pollen season (prophylactic); requires 4×/day dosing; now OTC; safe in pregnancy; generally less effective than INS but useful in patients wanting to avoid steroids.

Ipratropium bromide (Atrovent Nasal): Anticholinergic; reduces rhinorrhea only; useful for rhinorrhea-dominant AR or vasomotor rhinitis; does not help congestion or sneezing.

Back to Table of Contents

Allergen Immunotherapy (Allergy Shots and Drops)

Allergen immunotherapy (AIT) is the only treatment that modifies the underlying allergic disease rather than merely suppressing symptoms. It induces immune tolerance through repeated controlled allergen exposure, shifting the immune response from Th2 toward Th1 and regulatory T cell (Treg) profiles.

Subcutaneous immunotherapy (SCIT — allergy shots):

Sublingual immunotherapy (SLIT — allergy drops or tablets):

Back to Table of Contents

Environmental Control Strategies

Environmental control reduces allergen load — the foundation of AR management, especially for perennial allergens:

House dust mite reduction:

Pet dander:

Outdoor pollen:

HEPA filtration: High-Efficiency Particulate Air (HEPA) filters capture ≥99.97% of particles ≥0.3 microns (including pollen, mold spores, and dander fragments). Whole-house HEPA systems or portable room air purifiers with HEPA + carbon filters provide meaningful allergen reduction.

Back to Table of Contents

Research Papers

  1. Bousquet J et al. "Allergic Rhinitis and its Impact on Asthma (ARIA) 2008 update." Allergy. 2008;63 Suppl 86:8-160. PMID: 18331513
  2. Wheatley LM, Togias A. "Clinical practice. Allergic rhinitis." N Engl J Med. 2015 Jan 29;372(5):456-63. PMID: 25629743
  3. Brożek JL et al. "Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines: 2016 revision." J Allergy Clin Immunol. 2017 Apr;139(4):950-958. PMID: 28055919
  4. Yawn BP et al. "A systematic review and meta-analysis of intranasal corticosteroid therapy vs placebo for allergic rhinitis." JAMA Intern Med. 2015 Nov;175(11):1773-82. PMID: 26348956
  5. Penagos M et al. "Efficacy of subcutaneous and sublingual immunotherapy for allergic rhinitis in children: a systematic review with meta-analysis." Clin Exp Allergy. 2008 Nov;38(11):1532-41. PMID: 18727701
  6. Calderon MA et al. "Sublingual allergen immunotherapy: mode of action and its relationship with the safety profile." Allergy. 2012 Mar;67(3):302-11. PMID: 22150280
  7. Plaut M, Valentine MD. "Clinical practice. Allergic rhinitis." N Engl J Med. 2005 Nov 3;353(18):1934-44. PMID: 16267324
  8. Scadding GK et al. "BSACI guideline for the diagnosis and management of allergic and non-allergic rhinitis." Clin Exp Allergy. 2017 Jul;47(7):856-889. PMID: 28444913
  9. Bauchau V, Durham SR. "Prevalence and rate of diagnosis of allergic rhinitis in Europe." Eur Respir J. 2004 Nov;24(5):758-64. PMID: 15516668
  10. Okubo K et al. "Japanese guidelines for allergic rhinitis 2020." Allergol Int. 2020 Jul;69(3):331-345. PMID: 32388337
  11. Schatz M. "A survey of the burden of allergic rhinitis in the USA." Allergy. 2007 Nov;62 Suppl 85:9-16. PMID: 17927824
  12. Dykewicz MS, Wallace DV. "Diagnosis and treatment of allergic rhinitis: past, present, and future." Ann Allergy Asthma Immunol. 2018 Mar;120(3):272-280. PMID: 29477400

Back to Table of Contents

Connections

Back to Table of Contents